GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Instituto Rosenbusch SA (BUE:ROSE) » Definitions » Total Stockholders Equity

Instituto Rosenbusch (BUE:ROSE) Total Stockholders Equity : ARS2,842 Mil (As of Dec. 2024)


View and export this data going back to . Start your Free Trial

What is Instituto Rosenbusch Total Stockholders Equity?

Instituto Rosenbusch's Total Stockholders Equity for the quarter that ended in Dec. 2024 was ARS2,842 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Instituto Rosenbusch's Book Value per Share for the quarter that ended in Dec. 2024 was ARS66.74. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Instituto Rosenbusch's Debt-to-Equity for the quarter that ended in Dec. 2024 was 0.61.

Instituto Rosenbusch Total Stockholders Equity Historical Data

The historical data trend for Instituto Rosenbusch's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Instituto Rosenbusch Total Stockholders Equity Chart

Instituto Rosenbusch Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 382.65 344.82 1,129.80 1,914.48 2,842.42

Instituto Rosenbusch Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,914.48 3,235.09 3,487.75 3,667.16 2,842.42

Instituto Rosenbusch  (BUE:ROSE) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Instituto Rosenbusch's Book Value per Share for the quarter that ended in Dec. 2024 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(2842.423-0)/42.589
=66.74

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Instituto Rosenbusch's Debt-to-Equity for the quarter that ended in Dec. 2024 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(947.122 + 793.173) / 2842.423
=0.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Instituto Rosenbusch Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Instituto Rosenbusch's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Instituto Rosenbusch Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Instituto Rosenbusch SA (BUE:ROSE) » Definitions » Total Stockholders Equity
Comparable Companies
ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA TSE:4502 XSWX:GALD XSWX:SDZ NSE:DIVISLAB HKSE:03692 XTAE:TEVA SHSE:688506 BOM:500087 SZSE:000538 TSE:4507 UTHR NSE:TORNTPHARM BOM:500124 NBIX BOM:543904 BOM:532321
Traded in Other Exchanges
N/A
Address
Hipolito Yrigoyen 1628, Buenos Aires, ARG, C1089AAF
Website
https://www.rosenbusch.com
Instituto Rosenbusch SA is a pharmaceutical company based in Argentina. The company is engaged in the processing and industrialization of biological, chemical, pharmaceutical products of any kind, nature or destination, preferably for veterinary use or intended to combat pests and diseases of the agricultural exploitation. The company has line of products such as Biologicals and pharmaceuticals. Biologicals offer Campy 3, Cultivac 6M and Bovine Antibrucelosis. Pharmaceuticals offer Diclosan A Intrammamary, Diclosan S Intrammamary and Mastilina V-S.